Is LL-37 Antimicrobial Peptide FDA approved?

No. Not approved. It is available for research and investigational purposes only.

Is LL-37 Antimicrobial Peptide legal in Australia?

LL-37 Antimicrobial Peptide has no TGA approval for therapeutic use in Australia and is supplied strictly for laboratory research. Always verify current Poisons Standard scheduling with the TGA.

Is LL-37 Antimicrobial Peptide banned by WADA?

LL-37 Antimicrobial Peptide is not currently listed on the WADA Prohibited List, but athletes should confirm with their sport's governing body.

What is the half-life of LL-37 Antimicrobial Peptide?

The approximate half-life is ~Hours, a pharmacokinetic figure reported in the published literature.

Where can I buy LL-37 Antimicrobial Peptide for research?

Capital Precision Labs supplies LL-37 Antimicrobial Peptide for laboratory research use only. Products are independently tested by Janoshik Analytical, with certificates of analysis published for most products. Browse the available products on our site.

Limited EvidenceNot WADA Listed

AntimicrobialImmune

LL-37 Antimicrobial Peptide

Research Overview

Only human cathelicidin antimicrobial peptide; disrupts bacterial cell membranes via electrostatic binding and membrane pore formation; also modulates innate immune responses, promotes wound healing, and inhibits certain biofilm formation.

Compare to:KPV →BPC-157 →GHK-Cu →Thymosin Alpha-1 →

Half-life

~Hours

What is LL-37 Antimicrobial Peptide?

LL-37 is a naturally occurring antimicrobial peptide that has been extensively examined in preclinical research for its potential role in host defense and immune system regulation. Derived from the human cathelicidin precursor protein (hCAP18), LL-37 consists of a short chain of amino acids and is widely studied for its activity within innate immune pathways under controlled experimental conditions. As an endogenous peptide, it is recognized for its broad-spectrum antimicrobial properties, though many aspects of its biological function remain under active scientific investigation.

Across laboratory and animal-based models, LL-37 has been explored for its potential interactions with microbial membranes, as well as its role in modulating immune responses. Research has investigated how this peptide may influence signaling pathways involved in inflammation, chemotaxis, and cellular communication. Particular attention has been given to its interaction with immune cells such as macrophages, neutrophils, and epithelial cells, along with its potential involvement in cytokine regulation and barrier defense mechanisms.

In addition to its antimicrobial activity, LL-37 has been evaluated for its potential role in tissue-related processes within experimental settings. Some preclinical findings suggest that it may contribute to wound-healing pathways, angiogenesis, and cellular proliferation, as well as responses to environmental stressors and microbial challenges.

To support experimental consistency, LL-37 has been synthesized and stabilized for laboratory use, enabling researchers to investigate its structural behavior and biological activity under controlled conditions. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.

Compliance

Status & Legality

✓

Research UseLegal (research only)

Sold strictly as a research chemical for non-human, in-vitro, and laboratory use

✓

FDA StatusNot approved

FDA approved compound

✗

PrescriptionSchedule varies by jurisdiction

Prescription availability in Australia and internationally

In Australia, ll-37 antimicrobial peptide has no TGA approval for therapeutic use. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.

Pharmacology

Mechanism of Action

Support

Frequently Asked Questions

Available from Capital Precision Labs

LL-37 5mgfrom $51

✓ Independently tested✓ AUD pricing✓ Tracked delivery

References

1.Dürr, U. H. N., Sudheendra, U. S., & Ramamoorthy, A. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta (BBA) – Biomembranes.
2.Zanetti, M. (2004). Cathelicidins, multifunctional peptides of the innate immunity. Journal of Leukocyte Biology.
3.Nijnik, A., & Hancock, R. E. W. (2009). The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Current Opinion in Hematology.
4.Mookherjee, N., Rehaume, L. M., & Hancock, R. E. W. (2007). Cathelicidins and functional analogues as modulators of immune responses. Expert Opinion on Therapeutic Targets.
5.Koczulla, R., et al. (2003). An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. Journal of Clinical Investigation.
6.Heilborn, J. D., et al. (2003). The cathelicidin antimicrobial peptide LL-37 is involved in re-epithelialization of human skin wounds. Journal of Investigative Dermatology.
7.Scott, M. G., et al. (2002). An anti-infective peptide that selectively modulates the innate immune response. Nature Immunology.
8.Sørensen, O. E., et al. (2001). Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood.
9.Porcelli, F., et al. (2008). NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in solution. Biochemistry.
10.Voronko, O. E., et al. (2025). Antimicrobial peptides of the cathelicidin family: Focus on LL-37 and its modifications. International Journal of Molecular Sciences.

For research use only. Capital Precision Labs products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.

Other research overviews

AOD-9604 Peptide Argireline (Acetyl Hexapeptide-8)BPC-157, Thymosin Beta-4, and GHK-Cu Peptide Bronchogen Peptide Research Cardiogen Peptide Research Cartalax Peptide Research